Skip to main content

Elevated CAIX Expression is Associated with an Increased Risk of Distant Failure in Early-Stage Cervical Cancer.

Publication ,  Journal Article
Kirkpatrick, JP; Rabbani, ZN; Bentley, RC; Hardee, ME; Karol, S; Meyer, J; Oosterwijk, E; Havrilesky, L; Secord, AA; Vujaskovic, Z; Jones, EL ...
Published in: Biomark Insights
February 1, 2008

Tumor hypoxia is associated with adverse outcome in many malignancies. The goal of this study was to determine if elevated expression of carbonic anhydrase IX (CAIX), a biomarker of hypoxia, predicts for recurrence in early-stage cervical cancer. The charts of all patients with early-stage cervical cancer, primarily FIGO IB, treated by radical hysterectomy at our institution from 1988-2001 were reviewed. Adequate pathologic specimens from patients who recurred or who had at least three years follow-up and remained disease-free were stained for CAIX. An immunohistochemical score (IHC) was generated from the extent/intensity of staining. Outcome, as measured by freedom from recurrence (FFR), distant metastases (FFDM) and local recurrence (FFLR), was analyzed as a function of age, IHC, lymph node status (LN) and histology. Forty-two relapsing patients and 76 non-relapsing patients were evaluated. In univariate analysis, +LN, though not IHC or histology, was a significant predictor of any recurrence. Both +LN and higher IHC were associated with decreased FFDM but not FFLR. Patients with both +LN and elevated IHC more frequently exhibited distant metastases as first site of failure (5-year FFDM 50%) than patients with only +LN, elevated IHC or neither feature (70, 85 and 95%, respectively, p = 0.0004). In multivariable analysis, only +LN was significantly associated with poorer FFDM (hazard ratio 4.6, p = 0.0015) though there was a strong trend with elevated CAIX expression (p = 0.069). Elevated CAIX expression is associated with more frequent distant metastases in early-stage cervical cancer, suggesting that patients with this characteristic may benefit from more aggressive treatment.

Duke Scholars

Published In

Biomark Insights

DOI

ISSN

1177-2719

Publication Date

February 1, 2008

Volume

3

Start / End Page

45 / 55

Location

United States

Related Subject Headings

  • 3214 Pharmacology and pharmaceutical sciences
  • 3205 Medical biochemistry and metabolomics
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 1101 Medical Biochemistry and Metabolomics
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kirkpatrick, J. P., Rabbani, Z. N., Bentley, R. C., Hardee, M. E., Karol, S., Meyer, J., … Jones, E. L. (2008). Elevated CAIX Expression is Associated with an Increased Risk of Distant Failure in Early-Stage Cervical Cancer. Biomark Insights, 3, 45–55. https://doi.org/10.4137/bmi.s570
Kirkpatrick, John P., Zahid N. Rabbani, Rex C. Bentley, Matt E. Hardee, Seth Karol, Jeffrey Meyer, Egbert Oosterwijk, et al. “Elevated CAIX Expression is Associated with an Increased Risk of Distant Failure in Early-Stage Cervical Cancer.Biomark Insights 3 (February 1, 2008): 45–55. https://doi.org/10.4137/bmi.s570.
Kirkpatrick JP, Rabbani ZN, Bentley RC, Hardee ME, Karol S, Meyer J, et al. Elevated CAIX Expression is Associated with an Increased Risk of Distant Failure in Early-Stage Cervical Cancer. Biomark Insights. 2008 Feb 1;3:45–55.
Kirkpatrick, John P., et al. “Elevated CAIX Expression is Associated with an Increased Risk of Distant Failure in Early-Stage Cervical Cancer.Biomark Insights, vol. 3, Feb. 2008, pp. 45–55. Pubmed, doi:10.4137/bmi.s570.
Kirkpatrick JP, Rabbani ZN, Bentley RC, Hardee ME, Karol S, Meyer J, Oosterwijk E, Havrilesky L, Secord AA, Vujaskovic Z, Dewhirst MW, Jones EL. Elevated CAIX Expression is Associated with an Increased Risk of Distant Failure in Early-Stage Cervical Cancer. Biomark Insights. 2008 Feb 1;3:45–55.

Published In

Biomark Insights

DOI

ISSN

1177-2719

Publication Date

February 1, 2008

Volume

3

Start / End Page

45 / 55

Location

United States

Related Subject Headings

  • 3214 Pharmacology and pharmaceutical sciences
  • 3205 Medical biochemistry and metabolomics
  • 1115 Pharmacology and Pharmaceutical Sciences
  • 1101 Medical Biochemistry and Metabolomics